```html

Hodgkin’s Disease (Nodular Sclerosis) – A Patient‑Friendly Guide

Overview

Hodgkin’s disease (also called Hodgkin lymphoma, HL) is a cancer that begins in the lymphatic system, the network that helps the body fight infection. Nodular sclerosis (NS) is the most common histologic subtype, accounting for about 60–70 % of all HL cases in the United States and Europe.

Typical characteristics of nodular sclerosis Hodgkin lymphoma (NS‑HL) include:

• Presence of large, atypical cells called Reed‑Stenberg cells within fibrous “sclerotic” bands.
• Usually forms a “nodular” (lumpy) pattern when examined under a microscope.

Who it affects

• Age: peak incidence between 15–35 years and a second, smaller peak after age 55.
• Gender: slightly more common in males (≈55 % of cases).
• Geography: higher incidence in North America and Western Europe; lower in Asia and sub‑Saharan Africa.

According to the NCI, there were roughly 8,500 new cases of Hodgkin lymphoma in the United States in 2023, with NS‑HL representing the majority. The 5‑year survival for early‑stage NS‑HL exceeds 90 % with modern therapy, but outcomes fall for advanced disease.

Symptoms

Symptoms of nodular sclerosis Hodgkin lymphoma can be subtle at first and often mimic a mild infection. Below is a complete list with brief explanations.

General (B‑symptoms)

• Fever – Unexplained, often low‑grade fever that comes and goes without an obvious cause.
• Night sweats – Drenching sweats that require changing bedclothes or shirts.
• Weight loss – Unintentional loss of >10 % of body weight over 6 months.

Localized lymph‑node findings

• Painless swelling of lymph nodes, most commonly in the neck (cervical), under the arms (axillary), or above the collarbone (supraclavicular).
• Hard, rubbery texture that does not move easily with surrounding tissue.

Chest‑related symptoms (common in NS‑HL)

• Persistent cough or hoarseness caused by mediastinal (central chest) lymph node enlargement.
• Shortness of breath or chest tightness, especially when the mass compresses the airway.
• Difficulty swallowing (dysphagia) if the mass presses on the esophagus.

Other possible findings

• Fatigue or feeling unusually tired.
• Itchy skin (pruritus) without rash.
• Rarely, swelling of the abdomen (splenomegaly) or liver.

Causes and Risk Factors

The exact cause of Hodgkin lymphoma remains unknown, but research points to a combination of genetic, environmental, and infectious factors.

Infectious agents

• Epstein‑Barr virus (EBV) – Detected in the Reed‑Stenberg cells of 20‑50 % of NS‑HL cases, especially in younger patients and those from low‑income regions (CDC, 2022).
• Human immunodeficiency virus (HIV) – Increases overall lymphoma risk, though NS‑HL is less common than other subtypes in HIV‑positive individuals.

Genetic susceptibility

• Family history of Hodgkin lymphoma or other lymphoid cancers modestly raises risk (≈1.5‑fold).
• Specific HLA alleles (e.g., HLA‑DR2) have been linked to a higher likelihood of developing NS‑HL.

Environmental & lifestyle factors

• Previous radiation exposure – Survivors of childhood cancers who received high‑dose radiation have a 5‑10 % lifetime risk of HL.
• Immune suppression – Organ‑transplant recipients on chronic immunosuppressants show increased lymphoma rates.
• Smoking – Data are mixed, but some studies suggest a modest association with mediastinal disease.

Who is at higher risk?

• Adolescents and young adults (15‑35 y) – peak incidence for NS‑HL.
• People with a documented EBV infection during childhood who later develop a strong immune response.
• Individuals with a first‑degree relative diagnosed with Hodgkin lymphoma.

Diagnosis

Because early symptoms are nonspecific, a systematic approach is needed to confirm NS‑HL and stage the disease.

Clinical assessment

• Detailed medical history (including B‑symptoms, exposure to EBV, prior radiation).
• Physical examination focusing on lymph‑node groups, spleen, liver, and chest.

Imaging studies

• CT scan (neck, chest, abdomen, pelvis) – Evaluates size and location of nodal masses.
• PET‑CT (18F‑FDG) – Gold standard for staging; highlights metabolically active disease and guides treatment response.
• MRI – Useful for evaluating spinal or brain involvement, though rare in NS‑HL.

Laboratory tests

• Complete blood count (CBC) with differential.
• Erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) – Often elevated with B‑symptoms.
• Liver and kidney function panels – Baseline before chemotherapy.
• Serology for EBV (VCA‑IgG, EBV‑DNA) – May aid in prognosis.

Definitive tissue diagnosis

1. Excisional lymph‑node biopsy – Preferred method; removes an entire node for thorough histologic evaluation.
2. Core needle biopsy – Accepted when excision is not feasible, but may miss the characteristic Reed‑Stenberg cells.
3. Pathology review – Looks for the hallmark nodular pattern, lacunar‑type Reed‑Stenberg cells, and fibrous bands.
4. Immunohistochemistry – CD30 and CD15 positivity confirm classic Hodgkin lymphoma.

Staging

The Ann Arbor staging system (I‑IV) combined with “A” or “B” designation (absence or presence of B‑symptoms) is used to plan therapy.

Treatment Options

Therapy has evolved dramatically; most patients achieve cure with a combination of chemotherapy, targeted radiation, and supportive care.

First‑line chemotherapy

• ABVD regimen (Adriamycin/doxorubicin, Bleomycin, Vinblastine, Dacarbazine) – Standard for early‑stage (I‑II) and many advanced cases. Usually given every 2 weeks for 4–6 cycles.
• BEACOPP escalated – More intensive (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) – Considered for high‑risk advanced disease, but carries higher toxicity.

Radiation therapy

• Involved‑site radiotherapy (ISRT) of 20‑30 Gy to initial disease sites, most commonly the mediastinum in NS‑HL.
• Modern techniques (IMRT, proton therapy) limit exposure to heart, lungs, and breast tissue—critical for young patients.

Targeted and immunotherapy (relapsed/refractory disease)

• Brentuximab vedotin – Anti‑CD30 antibody‑drug conjugate, approved after failure of ≥2 chemotherapy lines.
• Nivolumab / pembrolizumab – PD‑1 checkpoint inhibitors that have shown durable responses in relapsed HL.
• Clinical trials – Ongoing studies explore CAR‑T cell therapy and novel checkpoint inhibitors.

Supportive care & lifestyle measures

• Antiemetics (e.g., ondansetron) to prevent chemotherapy‑induced nausea.
• Growth‑factor support (G‑CSF) for patients with high risk of neutropenia.
• Vaccinations – Influenza annually; pneumococcal after chemotherapy; avoid live vaccines for 6 months post‑treatment.
• Exercise & nutrition – Light to moderate activity as tolerated, high‑protein diet to aid recovery.

Living with Hodgkin's Disease (Nodular Sclerosis)

Managing day‑to‑day life while undergoing treatment and during survivorship involves practical steps.

During treatment

• Appointment tracking – Keep a calendar of chemo dates, labs, and radiation sessions.
• Medication log – Note doses of chemo, anti‑nausea meds, pain relievers, and any over‑the‑counter supplements.
• Hydration – Aim for 2–3 L of fluids daily unless contraindicated.
• Infection prevention – Wash hands frequently, avoid crowded places when neutrophil counts are low, and wear a mask during flu season.
• Fatigue management – Schedule rest periods, prioritize tasks, and consider short naps.
• Psychosocial support – Join a lymphoma support group or seek counseling to address anxiety and depression.

After treatment (survivorship)

• Regular follow‑up: CT or PET scans at 6‑month intervals for the first 2 years, then annually up to 5 years per NCCN guidelines.
• Cardiac monitoring: Echocardiogram or MUGA scan every 2–3 years if anthracyclines were used.
• Secondary‑cancer screening: Annual breast MRI for women who received chest radiation before age 30; skin examinations for long‑term immunosuppression.
• Fertility considerations: Discuss sperm banking or egg/embryo preservation before chemotherapy.
• Maintain healthy lifestyle: Balanced diet, weight control, smoking cessation, and regular physical activity (150 min/week moderate intensity).

Prevention

Because the exact cause is unknown, primary prevention is limited, but risk reduction strategies are available.

• EBV awareness – While you cannot avoid infection, early treatment of infectious mononucleosis reduces prolonged immune activation.
• Limit unnecessary radiation – Discuss alternative imaging (e.g., MRI, ultrasound) with your doctor when appropriate.
• Healthy immune system – Adequate sleep, balanced nutrition, and regular exercise support immune surveillance.
• Avoid tobacco – Smoking is linked to many cancers, including lymphomas.
• Vaccinations – Stay up to date on flu, COVID‑19, and HPV vaccines to reduce chronic immune stimulation.

Complications

If not treated promptly, or if treatment side‑effects are not managed, several complications can arise.

• Airway obstruction – Mediastinal mass compresses trachea, leading to breathing difficulty.
• Spinal cord compression – Rare, but possible with posterior mediastinal nodes.
• Infections – Neutropenia from chemotherapy increases risk of bacterial and fungal infections.
• Infertility – Alkylating agents and radiation can impair gonadal function.
• Secondary malignancies – Risk of solid tumors (breast, lung, thyroid) and acute myeloid leukemia after high‑dose chemo/radiation.
• Cardiovascular disease – Anthracycline‑related cardiomyopathy and radiation‑induced coronary artery disease may appear years later.
• Long‑term fatigue and psychosocial distress – Common in survivors; requires multidisciplinary management.

When to Seek Emergency Care

References

• Mayo Clinic. Hodgkin lymphoma: Symptoms & causes. Accessed May 2026.
• National Cancer Institute. Hodgkin Lymphoma—Fact Sheet. 2024.
• Cleveland Clinic. Hodgkin Lymphoma Overview. 2025.
• World Health Organization. Hodgkin lymphoma fact sheet. 2023.
• Schmitz N, et al. “EBV‑positive Hodgkin lymphoma: clinical and biological features.” Blood. 2022;140(12):1253‑1262.
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 3.2025.
• U.S. Centers for Disease Control and Prevention. Epstein‑Barr Virus (EBV) and Cancer. 2022.

```